Biochemical Basis and Therapeutic Relevance of Cathepsins in Cancer: Recent Advances
4 affiliations
- 1Department of Pharmacy, University of Salerno, Via G. Paolo II, 84084 Fisciano, Italy
- 2Medicum, Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, P.O. Box 63, FIN-00014 Helsinki, Finland
- 3Minerva Foundation Institute for Medical Research, Biomedicum Helsinki 2U, FIN-00290 Helsinki, Finland
- 4Department of Medicine, Digestive Health Research Institute, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
Abstract
Background/Objectives: Cathepsins, a family of lysosomal proteases essential for cellular proteostasis, have functions that extend beyond canonical degradation and recycling processes. Their dysregulation has been strongly associated with tumorigenesis, where cathepsins promote multiple hallmarks of cancer, including extracellular matrix remodeling, invasion, proliferation, and inflammation. Both intracellular and extracellular cathepsin activities contribute to tumor microenvironment shaping and influence the response to anticancer therapies, particularly chemoresistance. This review aims to summarize current knowledge on the biochemical regulation of cathepsins in cancer and evaluate their potential as therapeutic targets. Methods: A comprehensive literature analysis was conducted, focusing on recent in vitro, in vivo, and translational studies examining cathepsins’ functions, substrate specificity, biochemical pathways, and pharmacological modulations. Special attention was given to research addressing inhibitor development, therapeutic targeting strategies, and challenges associated with selectivity, delivery, and model variability. Results: Evidence indicates that cathepsins exhibit a multifaceted role in cancer. Extracellular cathepsins facilitate matrix degradation and metastatic dissemination, while intracellular cathepsins regulate key signaling networks that promote tumor cell survival, proliferation, autophagy, and inflammatory responses. Furthermore, cathepsins contribute to tumor microenvironment remodelling and modulate sensitivity to chemotherapy, supporting multiple mechanisms of therapy resistance. Although preclinical studies highlight promising therapeutic opportunities, significant limitations persist, including poor inhibitor specificity, challenges in drug delivery, compensatory activation among cathepsin isoforms that may sustain overlapping proteolytic functions, and heterogeneous responses across tumor types. Conclusions: Targeting cathepsins is an emerging strategy in oncology, but effective translation requires a deeper understanding of the complex biochemical networks they regulate. Given their broad and interconnected roles, clarifying these pathways is essential to anticipate global effects and potential toxicities. Future work should therefore define this molecular hub and develop approaches that ensure selective and safe cathepsin modulation.
Related
- Biochemical Characteristics of the Vascular Microenvironment in Pathological Conditions and Precision Therapeutic Strategies
- Aquaporin water channels: distribution, physiology, pathophysiology, and relevance as therapeutic targets.
- Functional Autoantibodies Against G-Protein-Coupled Receptors: Insights into Molecular Mechanisms, Clinical Relevance and Therapeutic Perspectives
- Advances in therapeutic oligonucleotide conjugates
- Spatial multi-omics analyses of the tumor immune microenvironment: advances and novel therapeutic avenues.
BibTeX
@article{vietri2026biochemical,
title = {{Biochemical Basis and Therapeutic Relevance of Cathepsins in Cancer: Recent Advances}},
author = {Mariapia Vietri and Alessia Delizia and Tania Ciaglia and Carla Sardo and Simona Musella and Veronica Di Sarno and Carmine Ostacolo and Ornella Moltedo and Dan Lindholm and Mario Felice Tecce and Pietro Campiglia and Alessia Bertamino and Maria Rosaria Miranda and Vincenzo Vestuto},
journal = {Biomolecules},
year = {2026},
month = nov,
doi = {10.3390/biom16111629},
url = {https://www.mdpi.com/2218-273X/16/11/1629},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Biochemical Basis and Therapeutic Relevance of Cathepsins in Cancer: Recent Advances
AU - Mariapia Vietri
AU - Alessia Delizia
AU - Tania Ciaglia
AU - Carla Sardo
AU - Simona Musella
AU - Veronica Di Sarno
AU - Carmine Ostacolo
AU - Ornella Moltedo
AU - Dan Lindholm
AU - Mario Felice Tecce
AU - Pietro Campiglia
AU - Alessia Bertamino
AU - Maria Rosaria Miranda
AU - Vincenzo Vestuto
PY - 2026
DA - 2026/11/08
JO - Biomolecules
DO - 10.3390/biom16111629
UR - https://www.mdpi.com/2218-273X/16/11/1629
AB - Background/Objectives: Cathepsins, a family of lysosomal proteases essential for cellular proteostasis, have functions that extend beyond canonical degradation and recycling processes. Their dysregulation has been strongly associated with tumorigenesis, where cathepsins promote multiple hallmarks of cancer, including extracellular matrix remodeling, invasion, proliferation, and inflammation. Both intracellular and extracellular cathepsin activities contribute to tumor microenvironment shaping and influence the response to anticancer therapies, particularly chemoresistance. This review aims to summarize current knowledge on the biochemical regulation of cathepsins in cancer and evaluate their potential as therapeutic targets. Methods: A comprehensive literature analysis was conducted, focusing on recent in vitro, in vivo, and translational studies examining cathepsins’ functions, substrate specificity, biochemical pathways, and pharmacological modulations. Special attention was given to research addressing inhibitor development, therapeutic targeting strategies, and challenges associated with selectivity, delivery, and model variability. Results: Evidence indicates that cathepsins exhibit a multifaceted role in cancer. Extracellular cathepsins facilitate matrix degradation and metastatic dissemination, while intracellular cathepsins regulate key signaling networks that promote tumor cell survival, proliferation, autophagy, and inflammatory responses. Furthermore, cathepsins contribute to tumor microenvironment remodelling and modulate sensitivity to chemotherapy, supporting multiple mechanisms of therapy resistance. Although preclinical studies highlight promising therapeutic opportunities, significant limitations persist, including poor inhibitor specificity, challenges in drug delivery, compensatory activation among cathepsin isoforms that may sustain overlapping proteolytic functions, and heterogeneous responses across tumor types. Conclusions: Targeting cathepsins is an emerging strategy in oncology, but effective translation requires a deeper understanding of the complex biochemical networks they regulate. Given their broad and interconnected roles, clarifying these pathways is essential to anticipate global effects and potential toxicities. Future work should therefore define this molecular hub and develop approaches that ensure selective and safe cathepsin modulation.
SN - 2218-273X
ER -